Q-Line Biotech Ltd. (QBL), a developer and manufacturer of in‑vitro diagnostic (IVD) reagents, kits and point‑of‑care devices, announced a book‑building initial public offering of 6,253,200 equity shares at a face value of Rs 10 each. The issue seeks to mobilise up to Rs 214.48 crore, representing 26.81% of the company’s post‑IPO paid‑up capital.
IPO pricing, timeline and allocation
The price band for the offering is set between Rs 326 and Rs 343 per share. Applicants must subscribe for a minimum of 800 shares, with subsequent applications in multiples of 400 shares. The subscription window opens on 21 May 2026 and closes on 25 May 2026. Upon listing, the shares will trade on the NSE SME Emerge platform.
In a pre‑IPO placement earlier in May 2026, QBL raised Rs 27.44 crore by selling 800,000 shares at the top of the price band, Rs 343 per share. The issue is jointly lead‑managed by Hem Securities Ltd. and Share India Capital Services Pvt. Ltd., with Purva Sharegistry (India) Pvt. Ltd. acting as registrar. Hem Finlease Pvt. Ltd., a member of the HEM group, serves as market maker and syndicate member.
Use of proceeds and capital structure
Net proceeds from the offering are earmarked for three primary purposes: Rs 93.50 crore for working capital, Rs 90.00 crore to repay or pre‑pay certain borrowings, and the remaining amount for general corporate purposes. After the issue, the company’s paid‑up equity is expected to rise from Rs 17.07 crore to Rs 23.33 crore, implying a post‑issue market capitalisation of roughly Rs 800.16 crore if the upper price band is achieved.
Historically, QBL has issued equity at par value and has raised additional capital in price ranges of Rs 125 to Rs 417 between March 2019 and May 2026. Bonus issues were declared at a 2‑for‑1 ratio in March 2016 and a 9‑for‑1 ratio in August 2025. The average acquisition cost for promoters stands at Rs 0.00, Rs 0.04 and Rs 18.34 per share for the respective issuances.
Business overview and recent financial performance
Founded in 2013, Q‑Line Biotech supplies diagnostic equipment and IVD products to hospitals, diagnostic service providers and medical colleges, either directly or through distributors. Its product portfolio spans clinical chemistry, haematology, immunodiagnostics, molecular diagnostics and point‑of‑care devices. During the COVID‑19 pandemic, the firm expanded its range to include RT‑PCR kits, RNA extraction kits and VTM kits through collaborations with third‑party institutes and internal R&D.
The company maintains a research‑driven model, leveraging in‑house R&D and technical collaborations with international partners to manufacture reagents and equipment that meet stringent quality and certification standards. As of 31 March 2026, QBL employed 362 permanent staff and 223 contract workers, of whom 19 (5.25% of the permanent workforce) were stationed in R&D laboratories.
On a consolidated basis, QBL reported total income of Rs 184.81 crore and net profit of Rs 32.10 crore for FY 2023; Rs 206.45 crore and Rs 34.44 crore respectively for FY 2024; and Rs 322.58 crore with a net profit of Rs 28.13 crore for FY 2025. For the nine‑month period ending 31 December 2025 (9M‑FY26), the company posted total income of Rs 236.50 crore and a net profit of Rs 38.69 crore, indicating a sharp increase in earnings compared with the full FY 2025 results.
Profit‑after‑tax (PAT) margins declined from 17.56% in FY 2023 and 16.92% in FY 2024 to 8.97% in FY 2025, before rebounding to 16.65% in the 9M‑FY26 period. Return on net worth (RoNW) averaged Rs 25.00 per share over FY 2024‑25, with an average RoNW of 23.17% across the last two fiscal years. The issue is priced at a price‑to‑book value (P/BV) of 2.44 based on a NAV of Rs 140.81 per share as of 31 December 2025; however, post‑IPO NAV figures are not disclosed in the offer documents.
Using the FY 2026 earnings proxy, the IPO price translates to a price‑to‑earnings (P/E) multiple of 15.51, while the FY 2025 earnings imply a P/E of 28.44. Analysts in the source commentary suggest that the pricing reflects the strong nine‑month earnings, which may not be sustainable given the variability in profitability.
The company has not declared dividends for any of the reported periods and states that any future dividend policy will be “prudent,” contingent on financial performance and outlook. No listed peers are identified for benchmarking purposes.
Market perception and analyst view
Two merchant bankers associated with the issue have collectively handled 79 issues over the past three years, of which eight closed below the issue price on listing day. The commentary accompanying the prospectus notes that, despite top‑line growth, QBL’s bottom line showed a dip in FY 2025 due to extraordinary items amounting to Rs 16.97 crore and a contingent liability of Rs 61.64 crore as of 31 December 2025. Overall borrowings stood at Rs 242.57 crore at the same date, raising concerns about leverage.
Given the absence of listed comparables and the company’s reliance on a strong nine‑month earnings run‑rate to justify valuation, the review concludes that the issue appears fully priced. It recommends that well‑informed investors may allocate moderate funds for the long term, while remaining mindful of earnings sustainability and debt levels.
Be First to Comment